GGrantIndex
← Search

Pathology Core Facility Shared Resource

$313,684P30FY2024CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

ABSTRACT – PATHOLOGY CORE FACILITY The Pathology Core Facility (PCF) in the Robert H. Lurie Comprehensive Cancer Center (LCC) is a centralized, comprehensive facility that provides expertise in pathology and human tissue-based studies and is specifically dedicated to support the needs of the Lurie Cancer Center research community. The PCF provides access to high quality patient-derived biospecimens, routine histology laboratory tools and pathologic expertise to support basic and translational research and clinical trials. Each year, the PCF serves approximately 500 cancer research studies and clinical trials. In the last five years it has contributed to 253 scientific publications and 30 grant applications, including NCI-funded grants such as the SPORE in Prostate Cancer (P50 CA180995), the Center for Cancer Nanotechnology Excellence Center (U54 CA119341) and the Epigenomics Consortium for HIV-Associated Cancers (U54 CA221205). The PCF maintains rigorous standard operating procedures, laboratory methods, and technologies that ensure the highest quality services for a variety of established and emerging applications. The PCF is functionally divided into three units: the Core Lab, the Biorepository, and the Clinical Trials Unit. The Core Lab is accredited by the CAP (College of American Pathologists), and conducts all tasks in routine histology, immunohistochemistry for cancer biomarker development and digital pathology, and CLIA-compliant molecular work in DNA and RNA isolation from blood products and tissues. The Biorepository division procures, processes, stores and distributes well-characterized neoplastic and benign human tissues, blood products, and other body fluids from patients who have signed an IRB-approved consent. In addition, there is an organized systematic effort for generalized procurement and storage of most common solid cancers and hematologic malignancies, following NCI Best Practices for Biospecimen Resources guidelines. The Biorepository has developed detailed sample annotation, including pre-analytic variables, frozen section evaluation, specimen tracking, and quality controlled collection procedures, ensuring that clinically meaningful and reproducible data emerge from investigations that use PCF samples. The associated biorepository database is centralized and was created in collaboration with the Cancer Center’s Quantitative Data Sciences Core for easy access by investigators. The PCF-Clinical Trials Unit (PCF-CTU) consults with PIs and reviews all clinical protocols that involve collection of human tissue specimens. Their major responsibility is the procurement and processing of biospecimens for investigator-initiated clinical trials, industry-based clinical trials, and trials supported by a contract from the NCI Division of Cancer Prevention, as required per IRB approved protocols.

View original record on NIH RePORTER →